Evaluation of a Blood Biomarker to Try and Distinguish Between the Presence or Absence of Aggressive Prostate Cancer

Stopped early

Conditions studied: Prostate Cancer

In brief

A Laboratory Study to Evaluate Urine and Blood Biomarkers That Can Distinguish Between the Presence or Absence of Aggressive Prostate Cancer

Key facts

Study ID

NCT03256630

Run by

Genomic Health®, Inc.

People needed

128

Starts

2018-01-10

Expected to finish

2019-02-28

Last updated by the study team

2020-02-05

Who can join

Age: any. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Patient has been diagnosed with Prostate Cancer and is planning on having a Radical Prostatectomy performed at the Global Robotics Institute.
• Diagnostic PSA ≤ 20 ng/mL.
• Pathology report from most recent positive biopsy, prior to Radical Prostatectomy, is available.
• Ability to read and understand the informed consent form.
• Patient must have signed informed consent form

You may not qualify if…

• Any of the following active therapies received: radiation, chemotherapy, biologic agents, surgery, local therapies including cryotherapy or HIFU.
• Diagnostic PSA > 20 ng/mL or missing PSA.
• Patients who are unable or unwilling to provide informed consent.

Where it is running

• Florida Hospital Global Robotics Institute — Celebration, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.